Weekly and Daily GLP-1 Drugs Go Head-to-Head
Anne L. Peters, MD: Hi. I am Dr. Anne Peters at the American Diabetes Association (ADA) meetings in San Francisco. I am here with Dr. Kathleen Dungan, Associate Professor of Medicine at Ohio State University and the director of their clinical endocrine trials unit.
Could you tell us about some of the exciting research that you are presenting here at the ADA meeting?
Kathleen M. Dungan, MD, MPH: This study[1] was part of the AWARD-6 trial investigating the clinical efficacy, safety, and tolerability of dulaglutide given once weekly.
Dr. Peters: What is dulaglutide?
Dr. Dungan: Dulaglutide is a glucagon-like peptide-1 (GLP-1)-based therapy. It consists of 2 GLP-1 analogs that are linked to an IgG fragment, which gives it a very large size and a prolonged life.
Dr. Peters: This is another once-weekly GLP-1 receptor agonist that is not yet on the market, correct?
Dr. Dungan: That is correct. It has been submitted to the US Food and Drug Administration. This trial was a randomized controlled trial comparing once-weekly dulaglutide with once-daily liraglutide in a noninferiority design. It was a 26-week study. Patients had type 2 diabetes and were on metforminmonotherapy, and the primary endpoint was
Type 2 Diabetes Mellitus
Type 2 Diabetes Mellitus Clinical Practice Guidelines (SID/AMD, 2022)
Pediatric Type 2 Diabetes Mellitus
COMMENTARY
Once-Weekly Dulaglutide Effective for T2DM
Anne L. Peters, MD; Kathleen M. Dungan, MD, MPH
DisclosuresJune 20, 2014
Weekly and Daily GLP-1 Drugs Go Head-to-Head
Anne L. Peters, MD: Hi. I am Dr. Anne Peters at the American Diabetes Association (ADA) meetings in San Francisco. I am here with Dr. Kathleen Dungan, Associate Professor of Medicine at Ohio State University and the director of their clinical endocrine trials unit.
Could you tell us about some of the exciting research that you are presenting here at the ADA meeting?
Kathleen M. Dungan, MD, MPH: This study[1] was part of the AWARD-6 trial investigating the clinical efficacy, safety, and tolerability of dulaglutide given once weekly.
Dr. Peters: What is dulaglutide?
Dr. Dungan: Dulaglutide is a glucagon-like peptide-1 (GLP-1)-based therapy. It consists of 2 GLP-1 analogs that are linked to an IgG fragment, which gives it a very large size and a prolonged life.
Dr. Peters: This is another once-weekly GLP-1 receptor agonist that is not yet on the market, correct?
Dr. Dungan: That is correct. It has been submitted to the US Food and Drug Administration. This trial was a randomized controlled trial comparing once-weekly dulaglutide with once-daily liraglutide in a noninferiority design. It was a 26-week study. Patients had type 2 diabetes and were on metforminmonotherapy, and the primary endpoint was
Medscape Diabetes © 2014 WebMD, LLC
Cite this: Once-Weekly Dulaglutide Effective for T2DM - Medscape - Jun 20, 2014.
Tables
References
Authors and Disclosures
Authors and Disclosures
Co-Authors
Anne L. Peters, MD, CDE
Professor, Endocrinology, Keck School of Medicine, University of Southern California; Director, University of Southern California Clinical Diabetes Programs, Los Angeles, California
Disclosure: Anne L. Peters, MD, has disclosed the following relevant financial relationships:
Served as a consultant for: Amylin/Lilly; Abbott Diabetes Care; Becton, Dickinson and Company; Janssen Pharmaceuticals, Inc.; Medtronic, Inc.; Perrigo; Roche; Takeda Pharmaceuticals North America, Inc.; sanofi-aventis
Serve(d) as a speaker or a member of a speakers bureau for: Amylin/Lilly; NovoNordisk
Kathleen M. Dungan, MD, MPH
Associate Professor, Ohio State University; Associate Professor, Division of Endocrinology, Diabetes & Metabolism, Ohio State University Wexner Medical Center, Columbus, Ohio
Disclosure: Kathleen M. Dungan, MD, MPH, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Eli Lilly and Company
Received research grant from: Novo Nordisk; Merck & Co., Inc.
Royalty: Up to Date